Every treatment we prescribe is MHRA licensed for weight management and supplied by a GPhC registered pharmacy. Your prescriber recommends the option suited to your history, preferences and goals.
| Plan | Active ingredient | How taken | Dose range | Average loss in trials | Price a month |
|---|---|---|---|---|---|
| Mounjaro | Tirzepatide | Weekly injection | 2.5 mg to 15 mg | Up to 21% at 72 weeks (SURMOUNT-1) | From £139 |
| Wegovy | Semaglutide | Weekly injection | 0.25 mg to 7.2 mg | About 15% at 68 weeks (STEP 1). Up to 20.7% on 7.2 mg (STEP UP) | From £69 |
| Wegovy pill | Oral semaglutide | Daily tablet | 1.5 mg to 25 mg | About 15% at 68 weeks (OASIS 1) | From £79 |
| Foundayo pill | Orforglipron | Daily tablet | 0.8 mg to 17.2 mg | About 12% at 72 weeks (ATTAIN-1) | From £79 |
Mounjaro leads the trial results, with up to 21% average loss at the highest dose. Wegovy 7.2 mg is close behind at 20.7%.
The Wegovy pill and Foundayo are daily tablets. Foundayo has no fasting rules. The Wegovy pill is taken on an empty stomach with a short wait before breakfast.
Semaglutide (Wegovy) has the most published safety data in this group, including a large cardiovascular outcomes trial.
Wegovy starts at £69 a month on the starter dose. See the price list for every dose.
Mounjaro can reduce absorption of the contraceptive pill at dose changes. If the pill is your method, Wegovy or Foundayo may suit better.
Reflux, gallbladder problems, diabetes medicines and past pancreatitis all shape the recommendation. The health check covers each one.
From£139a month
Up to 21% average weight loss in the SURMOUNT-1 trial at 72 weeks
From£69a month
About 15% average weight loss in the STEP 1 trial at 68 weeks
From£79a month
About 15% average weight loss in the OASIS 1 trial at 68 weeks
From£79a month
About 12% average weight loss in the ATTAIN-1 trial at 72 weeks
Daily liraglutide (Saxenda, or generic Nevolat) and orlistat capsules are older licensed treatments. They cost less and produce smaller average losses, around 8% for liraglutide and 5 to 10% over a year for orlistat. We prescribe them when a weekly pen or daily GLP-1 tablet is unsuitable.
Each page is checked against the UK licence for the medicine. Read our editorial policy.
